EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Current and Future Therapeutical Options in Alport Syndrome

Jana Reiterová, Vladimír Tesař iD

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms24065522 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Jana Reiterová und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, First Faculty of Medicine, Charles University, General University Hospital in Prague, 128 08 Prague, Czech Republic. Hauptthemen laut MEDLINE: Nephritis, Hereditary, Renal Insufficiency, Chronic, Sodium-Glucose Transporter 2 Inhibitors. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: General Teaching Hospital grant RVO-VFN, Charles University, First Faculty of Medicine grant project Progres, Charles University, First Faculty of Medicine.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Alport syndrome (AS) is a hereditary kidney disease caused by pathogenic variants in COL4A3 and COL4A4 genes with autosomal recessive or autosomal dominant transmission or in the COL4A5 gene with X-linked inheritance. Digenic inheritance was also described. Clinically it is associated with microscopic hematuria, followed by proteinuria and chronic renal insufficiency with end-stage renal disease in young adults. Nowadays, there is no curative treatment available. The inhibitors of RAS (renin-angiotensin system) since childhood slow the progression of the disease. Sodium-glucose cotransporter-2 inhibitors seem to be promising drugs from DAPA-CKD (dapagliflozin–chronic kidney disease) study, but only a limited number of patients with Alport syndrome was included. Endothelin type A receptor and angiotensin II type 1 receptor combined inhibitors, and lipid-lowering agents are used in ongoing studies in patients with AS and focal segmental glomerulosclerosis (FSGS). Hydroxychloroquine in AS is studied in a clinical trial in China. Molecular genetic diagnosis of AS is crucial not only for prognosis prediction but also for future therapeutic options. Different types of mutations will require various types of gene, RNA, or protein therapy to improve the function, the of final protein product.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Nephritis, HereditaryRenal Insufficiency, ChronicSodium-Glucose Transporter 2 InhibitorsChildHumansYoung AdultAutoantigensCollagen Type IVHematuriaMutation

Stichwörter der Autor:innen

Alport syndromegenetherapy

Substanzen

AutoantigensCollagen Type IVSodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • Department of Nephrology, First Faculty of Medicine, Charles University, General University Hospital in Prague, 128 08 Prague, Czech Republic.
  • First Faculty of Medicine, Institute of Biology and Medical Genetics, Charles University, General University Hospital in Prague, 128 08 Prague, Czech Republic.

ORCID-Profile: Vladimír Tesař

Förderung

  • General Teaching Hospital grant RVO-VFN
  • Charles University, First Faculty of Medicine grant project Progres
  • Charles University, First Faculty of Medicine
  • Ministry of Health, Czech Republic, Research organization
  • General University Hospital in Prague

Zitieren

APA

Reiterová, J., & Tesař, V. (2023). Current and Future Therapeutical Options in Alport Syndrome. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24065522

Vancouver

Reiterová J, Tesař V. Current and Future Therapeutical Options in Alport Syndrome. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24065522

BibTeX
@article{Reiterov2023,
  author = {Reiterová, Jana and Tesař, Vladimír},
  title = {Current and Future Therapeutical Options in Alport Syndrome},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms24065522}
}
Kostenlos starten →